Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma names Cynthia Butitta as CFO

She helped broker Pfizer’s takeover of NextWave Pharmaceuticals

Kite Pharma has named industry veteran Cynthia Butitta as chief financial officer.

Butitta was most recently chief financial officer of NextWave Pharmaceuticals and played a key role in the company's acquisition by Pfizer in October 2012.

Her other previous roles include chief financial officer and chief operating officer of Telik where she was responsible for securing over $450m through an initial public offering (IPO). She was also VP of finance at the biotech Connetics.

Kite Pharma is a biotech specialist in the burgeoning area of cancer immunotherapy products.

It has made a number of recent senior appointments in recent months – including several immunotherapy experts to its scientific advisory board and a chief medical officer – and Butitta is the latest hire to bolster its senior team.

“As a leading company in the emerging and highly promising field of immunotherapy, Kite has the opportunity to play a pivotal role in changing the way we approach cancer,” said Butitta.

10th January 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics